Raymond James Associates buys $281.2 Million stake in Johnson & Johnson (JNJ)

Johnson & Johnson (JNJ) : Raymond James Associates scooped up 247,537 additional shares in Johnson & Johnson during the most recent quarter end , the firm said in a disclosure report filed with the SEC on May 12, 2016. The investment management firm now holds a total of 2,475,788 shares of Johnson & Johnson which is valued at $281.2 Million.Johnson & Johnson makes up approximately 0.96% of Raymond James Associates’s portfolio.

Other Hedge Funds, Including , Edmond De Rothschild Holding S.a. reduced its stake in JNJ by selling 92,812 shares or 35.52% in the most recent quarter. The Hedge Fund company now holds 168,519 shares of JNJ which is valued at $19.1 Million. Johnson & Johnson makes up approx 0.65% of Edmond De Rothschild Holding S.a.’s portfolio.Seizert Capital Partners reduced its stake in JNJ by selling 80,787 shares or 16.39% in the most recent quarter. The Hedge Fund company now holds 412,054 shares of JNJ which is valued at $46.8 Million. Johnson & Johnson makes up approx 1.63% of Seizert Capital Partners’s portfolio.Tealwood Asset Management Inc reduced its stake in JNJ by selling 1,313 shares or 2.69% in the most recent quarter. The Hedge Fund company now holds 47,451 shares of JNJ which is valued at $5.4 Million. Johnson & Johnson makes up approx 2.42% of Tealwood Asset Management Inc’s portfolio.Telemus Capital boosted its stake in JNJ in the latest quarter, The investment management firm added 26,066 additional shares and now holds a total of 28,028 shares of Johnson & Johnson which is valued at $3.1 Million. Johnson & Johnson makes up approx 0.52% of Telemus Capital’s portfolio.

Johnson & Johnson opened for trading at $112.2 and hit $112.92 on the upside on Friday, eventually ending the session at $112.64, with a gain of 0.53% or 0.59 points. The heightened volatility saw the trading volume jump to 74,35,203 shares. Company has a market cap of $309,833 M.

On the company’s financial health, Johnson & Johnson reported $1.68 EPS for the quarter, beating the analyst consensus estimate by $ 0.03 according to the earnings call on Apr 19, 2016. Analyst had a consensus of $1.65. The company had revenue of $17482.00 million for the quarter, compared to analysts expectations of $17491.02 million. The company’s revenue was up .6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.56 EPS.

Many Wall Street Analysts have commented on Johnson & Johnson. Standpoint Research Initiated Johnson & Johnson on May 20, 2016 to “Sell”, Price Target of the shares are set at $94.Company shares were Reiterated by RBC Capital Mkts on Apr 20, 2016 to “Outperform”, Firm has raised the Price Target to $ 125 from a previous price target of $122 .Company shares were Reiterated by Piper Jaffray on Apr 20, 2016 to “Neutral”, Firm has raised the Price Target to $ 106 from a previous price target of $105 .

Johnson & Johnson is a holding company. The Company is engaged in the research and development manufacture and sale of a range of products in the health care field. The Company has more than 265 operating companies conducting business around the world. The Company’s primary focus is products related to human health and well-being. The Company is organized into three business segments: Consumer Pharmaceutical and Medical Devices. The Company’s subsidiaries operate 134 manufacturing facilities occupying approximately 21.5 million square feet of floor space. The Company’s research facilities are located in the United States Belgium Brazil Canada China France Germany India Israel Japan the Netherlands Singapore Switzerland and the United Kingdom.

Leave a Reply

Johnson & Johnson - Is it time to Sell?

Top Brokerage Firms are advising their investors on Johnson & Johnson. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.